All News

Information on new products from Endo Pharmaceuticals, Envisionier Medical Technologies, biolitec, Inc., and Mission Pharmacal.

A new noninvasive vacuum protocol for erectile dysfunction patients using an inflatible penile prosthesis can prevent penile shortening.

Major complications detected by computed tomography performed immediately following percutaneous nephrolithotomy are uncommon. However, certain major complications can be detected early.

Endo Pharmaceuticals has announced the reintroduction of valrubicin (VALSTAR) intravesical therapy for the treatment of Bacillus Calmette-Guérin (BCG)-refractory carcinoma in situ (CIS) of the bladder for whom immediate removal of the bladder would be associated with unacceptable medical risks.

A minimally invasive form of nerve stimulation appears to be an effective alternative to drug therapy in patients with overactive bladder, study results show.

Children on the high-fat ketogenic diet to control epileptic seizures can prevent the kidney stones caused by the diet if they take a daily supplement of potassium citrate (Polycitra K), according to research from Johns Hopkins Children?s Center, Baltimore.

Body mass in younger and older adulthood, and weight gain between these periods, may influence a man?s risk for prostate cancer, and the risk varies among different ethnic populations, report researchers from the University of Hawaii, Honolulu.

Researchers have reported that a virus known to cause leukemia and sarcomas in animals has been found in malignant human prostate cancer cells.

A comparison of outcomes of different eras of conservative treatment for localized prostate cancer indicates that overall and prostate cancer-specific survival rates are higher for men diagnosed from 1992 to 2002 compared with men diagnosed in the 1970s and 1980s.

EDAP TMS SA has received FDA clearance to market its newly designed Sonolith I-Sys lithotripter in the United States.

In high-risk men, PSA testing performs optimally when conducted intelligently and combined with prompt, effective, high-quality treatment, according to updated clinical practice guidelines on early detection of prostate cancer from the National Comprehensive Cancer Network.

Obesity plays no favorites when it comes to increasing the risk of prostate cancer recurrence after surgery, according to researchers at Duke University Medical Center, Durham, NC. Being overweight is equally bad for African-American and white men.

Since its introduction in 1986, PSA screening has resulted in more than one million men being needlessly diagnosed and treated for prostate cancer, according to a study published online Aug. 31 in the Journal of the National Cancer Institute.

Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or with radiation therapy for treatment of prostate cancer have an associated increased risk of death, according to researchers at Brigham & Women's Hospital-Dana Farber Cancer Institute, Boston.

Dr. Jordan Dimitrakov discusses the use of memantine in chronic pelvic pain syndrome with Urology Times.

Dr. Williams and Dr. Nangia discuss the effects of cardiometabolic disorders in aging men.

Despite bringing lower rates of positive surgical margins and lower PSA nadirs, long-term neoadjuvant hormonal therapy did not lead to a difference in rates of PSA recurrence after 7 years.

Different areas of the brain are active in different chronic pain conditions, and now researchers have shown that those areas are distinctly different in patients with interstitial cystitis and chronic prostatitis/chronic pelvic pain syndrome.

Urologists from around the country give their opinions on health care reform.

Brachytherapy and radical prostatectomy are effective treatments for localized prostate cancer, but have different long-term functional effects, 13-year follow-up data show.

BPH and lower urinary tract symptoms are very common, increase as a function of age, and are often managed through watchful waiting.

Androgen deprivation therapy leads to an increased risk of bone fractures and other side effects of estrogen deficiency in men with prostate cancer, but those effects can be successfully treated with the use of an oral selective estrogen receptor modulator, suggest the results of a large, prospective, randomized tria presented at the AUA annual meeting in Chicago.

During our working years, we justify the negative impact of inflation by relying on the expectation that our incomes will rise at levels consistent with or above inflation. Unfortunately, many of today's physicians are experiencing just the opposite.

Twice-yearly injections of denosumab improved bone mineral density in men with prostate cancer treated with androgen deprivation therapy.

Discovery of the prostate carcinoma-specific gene has led to the development of a promising urine-based laboratory test for the disease.

In a phase II study, about 40% of men with clinically localized, high-risk prostate cancer were free of biochemical recurrence at 18 months when treated with neoadjuvant docetaxel (Taxotere) and ketoconazole followed by surgical excision, according to research presented at the AUA annual meeting.

Two of several studies presented by the same international team suggest that high-intensity focused ultrasound provides good biochemical-free survival at 5 years in patients treated in the absence of hormone therapy.